These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 15584770)

  • 1. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.
    Connor DF; Steingard RJ
    CNS Drugs; 2004; 18(14):1011-30. PubMed ID: 15584770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    Paediatr Drugs; 2006; 8(5):319-33. PubMed ID: 17037949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.
    Ermer JC; Adeyi BA; Pucci ML
    CNS Drugs; 2010 Dec; 24(12):1009-25. PubMed ID: 21090837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
    Prince JB
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Formulations of Stimulants: An Update for Clinicians.
    Steingard R; Taskiran S; Connor DF; Markowitz JS; Stein MA
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):324-339. PubMed ID: 31038360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):183-185. PubMed ID: 29125594
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
    Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
    Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.
    Döpfner M; Gerber WD; Banaschewski T; Breuer D; Freisleder FJ; Gerber-von Müller G; Günter M; Hässler F; Ose C; Rothenberger A; Schmeck K; Sinzig J; Stadler C; Uebel H; Lehmkuhl G
    Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I93-101. PubMed ID: 15322960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
    Hazell P
    Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
    Cortese S; D'Acunto G; Konofal E; Masi G; Vitiello B
    CNS Drugs; 2017 Feb; 31(2):149-160. PubMed ID: 28130762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for misuse and abuse of medications in ADHD: a review.
    Clemow DB; Walker DJ
    Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations.
    Childress AC; Komolova M; Sallee FR
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):937-974. PubMed ID: 31581854
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy.
    Mohammadi M; Akhondzadeh S
    Acta Med Iran; 2011; 49(8):487-98. PubMed ID: 22009816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.
    Wolraich ML; Doffing MA
    CNS Drugs; 2004; 18(4):243-50. PubMed ID: 15015904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.